# International study on COVID-19 Vaccine to assess Immunogenicity, Reactogenicity and Efficacy (InVITE)

> **NIH NIH N01** · LEIDOS BIOMEDICAL RESEARCH, INC. · 2021 · $8,758,469

## Abstract

This funding supports a multicenter study of COVID-19 vaccine immunogenicity and durability, and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections in people who receive a COVID-19 vaccine through their country’s national vaccination programs. The study will be conducted in international sites including those that participate in the Division of Clinical Research Special Projects. This study is unique in that it examines the immunogenicity of multiple different vaccination regimens (both initial and booster) across several countries.

## Key facts

- **NIH application ID:** 10505920
- **Project number:** 75N91019D00024-P00001-759102000025-3
- **Recipient organization:** LEIDOS BIOMEDICAL RESEARCH, INC.
- **Principal Investigator:** SALLY HUNSBERGER
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $8,758,469
- **Award type:** —
- **Project period:** 2020-09-28 → 2025-09-27

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10505920

## Citation

> US National Institutes of Health, RePORTER application 10505920, International study on COVID-19 Vaccine to assess Immunogenicity, Reactogenicity and Efficacy (InVITE) (75N91019D00024-P00001-759102000025-3). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10505920. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*